BR112013024585A8 - formas de dosagem farmacêutica de liberação controlada - Google Patents

formas de dosagem farmacêutica de liberação controlada

Info

Publication number
BR112013024585A8
BR112013024585A8 BR112013024585A BR112013024585A BR112013024585A8 BR 112013024585 A8 BR112013024585 A8 BR 112013024585A8 BR 112013024585 A BR112013024585 A BR 112013024585A BR 112013024585 A BR112013024585 A BR 112013024585A BR 112013024585 A8 BR112013024585 A8 BR 112013024585A8
Authority
BR
Brazil
Prior art keywords
dosage forms
pharmaceutical dosage
controlled release
release pharmaceutical
layer
Prior art date
Application number
BR112013024585A
Other languages
English (en)
Portuguese (pt)
Inventor
Haiyong Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of BR112013024585A8 publication Critical patent/BR112013024585A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013024585A 2011-03-25 2012-03-22 formas de dosagem farmacêutica de liberação controlada BR112013024585A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467824P 2011-03-25 2011-03-25
PCT/IB2012/000595 WO2012131463A2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
BR112013024585A8 true BR112013024585A8 (pt) 2018-01-09

Family

ID=46018006

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024585A BR112013024585A8 (pt) 2011-03-25 2012-03-22 formas de dosagem farmacêutica de liberação controlada

Country Status (24)

Country Link
US (1) US20140056979A1 (cg-RX-API-DMAC7.html)
EP (1) EP2688556B1 (cg-RX-API-DMAC7.html)
JP (1) JP5964940B2 (cg-RX-API-DMAC7.html)
KR (1) KR101619579B1 (cg-RX-API-DMAC7.html)
CN (1) CN103547259A (cg-RX-API-DMAC7.html)
AU (1) AU2012235878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013024585A8 (cg-RX-API-DMAC7.html)
CA (1) CA2831218C (cg-RX-API-DMAC7.html)
CY (1) CY1116579T1 (cg-RX-API-DMAC7.html)
DK (1) DK2688556T3 (cg-RX-API-DMAC7.html)
ES (1) ES2544735T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150835T1 (cg-RX-API-DMAC7.html)
HU (1) HUE026981T2 (cg-RX-API-DMAC7.html)
IL (1) IL228441B (cg-RX-API-DMAC7.html)
ME (1) ME02189B (cg-RX-API-DMAC7.html)
MX (1) MX350875B (cg-RX-API-DMAC7.html)
PH (1) PH12013501994A1 (cg-RX-API-DMAC7.html)
PL (1) PL2688556T3 (cg-RX-API-DMAC7.html)
PT (1) PT2688556E (cg-RX-API-DMAC7.html)
RS (1) RS54152B1 (cg-RX-API-DMAC7.html)
SI (1) SI2688556T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500209B (cg-RX-API-DMAC7.html)
WO (1) WO2012131463A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307862B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
JP7335870B2 (ja) * 2017-08-31 2023-08-30 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形
US12161754B2 (en) 2017-12-20 2024-12-10 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007907B1 (ko) * 1992-09-01 1995-07-21 동국제약 주식회사 치주질환 치료용 막형 국소약물송달제제
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
MXPA02007254A (es) * 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
AU2002227383B2 (en) * 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
CA2572491A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
US7434308B2 (en) * 2004-09-02 2008-10-14 International Business Machines Corporation Cooling of substrate using interposer channels
CN101232868A (zh) * 2005-04-19 2008-07-30 阿尔扎公司 曲马多和加巴喷丁的控释递药剂型
RU2008149702A (ru) * 2006-05-17 2010-06-27 Сандвик Интеллекчуал Проперти Аб (Se) Верхнеударный инструмент для сверления камня, стержень сверла и соединительный рукав
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2009012122A1 (en) * 2007-07-13 2009-01-22 Marvell World Trade Ltd. Method for shallow trench isolation
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN101933907A (zh) * 2009-06-30 2011-01-05 北京天衡药物研究院 新型骨架缓释片及其制备方法

Also Published As

Publication number Publication date
CA2831218A1 (en) 2012-10-04
US20140056979A1 (en) 2014-02-27
AU2012235878B2 (en) 2015-10-15
HUE026981T2 (en) 2016-08-29
HRP20150835T1 (hr) 2015-09-11
AU2012235878A1 (en) 2013-05-02
KR101619579B1 (ko) 2016-05-10
SI2688556T1 (sl) 2015-09-30
JP2014510094A (ja) 2014-04-24
DK2688556T3 (en) 2015-08-03
NZ616600A (en) 2015-07-31
IL228441B (en) 2019-05-30
ME02189B (me) 2016-02-20
PT2688556E (pt) 2015-09-11
CY1116579T1 (el) 2017-03-15
PH12013501994A1 (en) 2013-12-02
WO2012131463A2 (en) 2012-10-04
KR20130135973A (ko) 2013-12-11
EP2688556B1 (en) 2015-05-06
WO2012131463A3 (en) 2012-11-29
MX350875B (es) 2017-09-19
JP5964940B2 (ja) 2016-08-03
IL228441A0 (en) 2013-12-31
MX2013010987A (es) 2014-10-13
PL2688556T3 (pl) 2015-10-30
ZA201307862B (en) 2014-06-25
RS54152B1 (sr) 2015-12-31
ES2544735T3 (es) 2015-09-03
CA2831218C (en) 2017-01-17
CN103547259A (zh) 2014-01-29
EP2688556A2 (en) 2014-01-29
SMT201500209B (it) 2015-10-30

Similar Documents

Publication Publication Date Title
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
BRPI0714539B8 (pt) processo para obtenção de forma de dosagem farmaceutica de liberação prolongada de opioides
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CR20150326A (es) Inhibidores de autotaxina
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MX2019007391A (es) Sistema terapeutico transdermico que contiene asenapina.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
WO2014002058A3 (en) Complement pathway modulators and uses thereof
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
AR086395A1 (es) Envase para el tratamiento de patologias
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements